Source: Annual Congress 2002 - Asthma - Therapy and management -1
Disease area: Airway diseases

Abstract

Inhaled corticosteroides and oral theophilline are effective treatment for moderate asthma. The aim of this study was to compare the benefits and adverse rections of theophilline and aerosol beclomethasone spray.
Methods: We included 90 patients with mild to moderate asthma. 45 of them received beclomethasone dipropionate aerosol spray 250 μg two times per day during one year. The second group of 45 patients received theophilline twice per day in doses for optimum control of the disease. The main outcome measure were daily diary of symptomes and peak flow rates, supplemental bronchodilatator use, hospitals visits and absence from work, spiromtry measurements, methacholine tests.
Results: Both treatment strategies reduced symptoms and reduced absence from work and emergency treatment for asthma. Both had nearly normal pulmonary function. Beclomethason was significantly more effective in reducind symptoms, suplemental bronchodilatators and systemic corticosteroids doses. Theophillin caused more headache, insomnia, gastrointestinal distress and more patients had discontinued treatment because of the side effects.
Beclomethason caused more oropharyngeal candidiees and hoarsenes.
Theophyilline effectively controlled symptoms with recommended blood level. The risk/benefit profiles of these agents suggest that inhaled corticosteroids may be prefered agent.

Rating:

Share or cite this content

Citations should be made in the following way:
M. I. Boskovska, C. A. Busletic, Z. D. Goseva, Z. S. Arsovski (Skopje, Macedonia). Inhalation of beclomethason dipropionate spray compared with theophilline as primary treatment for chronic mild-to-moderate asthma. Eur Respir J 2002; 20: Suppl. 38, 381

Member's Comments

No comment yet.

Related content which might interest you: Inhalation of fluticasone propionate spray compared with theophilline as primary treatment for chronic mild to moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 500s Year: 2006 Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001 Nebulized beclomethasone dipropionate is as effective and as well tolerated than nebulized budesonide to prevent asthma exacerbations in infants Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001 Efficacy, safety and cost of using beclomethason dipropionate in patients with persistent moderate bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004 HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005 Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006 Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002 Salmeterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005 Clinical efficacy of seretide and beclomethasone dipropionate in patients with corticosteroid-dependent bronchial asthma and quality of life Source: Eur Respir J 2004; 24: Suppl. 48, 285s Year: 2004 Airway and systemic effects of hydrofluoroalkane formulations of high dose ciclesonide and fluticasone propionate in moderate persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004 A pharmaco-epidemiological audit of beclomethasone dipropionate extrafine aerosol in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 471s Year: 2002 Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001 Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006 The clinical effectiveness of HFA-beclomethasone dipropionate in children with moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 166s Year: 2004 Efficacy of inhaled ciclesonide compared with oral prednisolone in the treatment of asthma exacerbations Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006 Extrafine beclomethasone dipropionate aerosol therapy shows promising improved effect in treatment of children with stable asthma Source: Eur Respir J 2004; 24: Suppl. 48, 378s Year: 2004 Real-life effectiveness of beclomethasone diproprionate/formoterol extra-fine combination in adult patients with persistent asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011 Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma Source: Eur Respir J 2004; 24: 932-937 Year: 2004 Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001 Dosage tapering of inhalatory budesonide in subjects with mild-moerate persistent asthma treated with montelukast Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003